Midas Letter released a podcast interview with Rob Hutchison, CEO and chairman of biOasis Technologies Inc. (TSXV:BTI,OTCQX:BIOAF). In it, he discusses the company’s blood brain barrier technology, which “reliably delivers therapeutic compounds beyond the Blood Brain Barrier in mice so far.”

Hutchison states:

From our perspective, biOasis has over the last number of years … actually completed all of the ground-level experimental work that was necessary to advance this technology forward. It’s now been vetted by independent third parties, including industry itself — in other words, large pharma companies have evaluated the technology. So I think it provides an opportunity for immediate potential opportunities for shareholders and investors.

Click here to listen to the podcast at the Midas Letter site.